John Hussman's ACAD Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 126.0K shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $2.69 M, representing 0.58% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 11 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 84.0K shares. Largest reduction occurred in Q2 2023, reducing 31.0K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2023 | +93,000 | New Buy | 93,000 | $18.82 |
| Q2 2023 | -31,000 | Reduce 33.33% | 62,000 | $23.95 |
| Q3 2023 | -20,000 | Reduce 32.26% | 42,000 | $20.84 |
| Q3 2024 | -42,000 | Sold Out | 42,000 | $0.00 |
| Q3 2025 | +126,000 | New Buy | 126,000 | $21.34 |
John Hussman's ACADIA Pharmaceuticals Investment FAQs
John Hussman first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q1 2023, acquiring 93,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held ACADIA Pharmaceuticals Inc. (ACAD) for 11 quarters since Q1 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2025, adding 126,000 shares worth $2.69 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 126,000 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $2.69 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.58% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 126,000 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.